Medicare Drug Price Negotiation Insights and Implications
Explore the implications of Medicare's Drug Price Negotiation Program, its impact on costs, and the ongoing negotiations for 2028. Discover key details.
CMS Updates on Medicare Drug Price Negotiation and 340B Rebate Litigation
CMS announces changes to Medicare drug price negotiations; ongoing litigation surrounds 340B rebate model and state drug pricing laws, affecting Medicare Advantage plans and Part D reimbursement.
Impact of Expiring ACA Enhanced Premium Tax Credits on Marketplace Costs
Expiring ACA enhanced premium tax credits will significantly raise Marketplace health insurance premiums, especially for older enrollees and higher-income groups across many states.
Medicare Drug Price Negotiations Yield $12 Billion Savings on 15 Key Medications
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
Medicare Drug Price Negotiations Expand to 15 More Medications in 2027
CMS expands Medicare drug price negotiations to 15 more medications starting in 2027, including popular diabetes and weight loss treatments, aiming to reduce prescription costs and save Medicare billions.
Medicare Drug Price Negotiations Yield 44% Savings Under Inflation Reduction Act
Medicare's Inflation Reduction Act negotiations cut prices for 15 top prescription drugs by 44%, reducing out-of-pocket costs and impacting Medicare Part D and Part B markets.
CMS to Lower Prices on 15 Major Medicare Part D Drugs by 2027
CMS announces reduced prices for 15 key Medicare Part D drugs starting in 2027, following the Inflation Reduction Act negotiations, targeting major cost savings in Medicare spending.
Inflation Reduction Act Expected to Lower Medicare Part D Out-of-Pocket Costs for Specialty Drugs
New analysis shows Inflation Reduction Act provisions will reduce Medicare Part D out-of-pocket costs for specialty drugs etanercept, ustekinumab, and ibrutinib, improving affordability for beneficiaries.
Medicare Inflation Rebates: Extending Protections to Medicare Advantage Enrollees
Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.
Medicare Drug Costs Under Inflation Reduction Act: Implications Ahead
Explore how the Inflation Reduction Act impacts Medicare beneficiaries' access and costs for prescription medications, including significant changes in formulary access and cost-sharing for 2025.